BUZZ-Salarius Pharma falls as FDA puts cancer drug trial on partial clinical hold

Reuters07-11

** Shares of drug developer Salarius Pharmaceuticals

fall 20.8% to $2.17 premarket

** Co says FDA has placed a partial clinical hold on its early-stage trial studying its experimental drug seclidemstat in combination with chemotherapy drug azacitidine in adult patients with type of blood cancer

** No new patients may be enrolled at this time; currently enrolled patients may continue treatment and all study procedures if they are benefiting

** On July 9, researchers at The University of Texas MD Anderson Cancer Center (MDACC) notified co that a patient experienced unexpected serious adverse event - filing

** Co intends to support researchers at MDACC to analyze the available data and respond to questions submitted by the FDA

** Up to last close, stock down 47.26% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment